trending Market Intelligence /marketintelligence/en/news-insights/trending/j1vwea7w2v-hwwvsdpv_dq2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us
In This List

Atara's blood disorder therapy shown to improve survival in mid-stage trials


M&A rebound sparks optimism for near-term deal activity


Needham & Company is Now Available in the S&P Global Market Intelligence Aftermarket Research Collection


Banking Essentials Newsletter - February Edition


Message in a (Word)Cloud

Atara's blood disorder therapy shown to improve survival in mid-stage trials

Atara Biotherapeutics Inc. said Tab-cel, its investigational T cell immunotherapy, showed durable effects in patients infected with a certain tumor virus after undergoing transplant procedures in two mid-stage trials.

The phase 2 trials evaluated Tab-cel, or tabelecleucel, in patients with Epstein-Barr virus associated post-transplant lymphoproliferative disorder, or EBV-PTLD, after undergoing either a solid organ transplant or an allogeneic hematopoietic cell transplant, or HCT. These patients had failed initial treatment with Rituxan, or rituximab, Roche Holding AG's blood cancer drug.

Epstein-Barr virus is a common virus that causes infectious mononucleosis and is associated with certain cancers such as Burkitt lymphoma, immunoblastic lymphoma and nasopharyngeal carcinoma. Lymphoproliferative disorders refer to several conditions in which infection-fighting cells of the immune system, called lymphocytes, are produced in excessive quantities.

For the 35 patients with EBV-PTLD following a hematopoietic cell transplant who were treated with Tab-cel, 68% were alive for one year while 55% survived for three years. The average period of time that the patients were alive was not reached after 23.3 months of follow-up.

The expected median survival for patients with EBV-PTLD following HCT who have failed rituximab first-line therapy is 16 to 56 days.

Meanwhile, in the 14 patients with EBV-PTLD after a solid organ transplant, 64% survived for a year while 43% were alive for three years. The average survival period for the group was 21.3 months, versus the expected 12- to 13-month median survival in patients with EBV-PTLD following organ transplant who fail to achieve a complete response to initial treatment with rituximab.

Tab-cel reduced the disease in 69% of patients who had received a hematopoietic cell transplant and in 50% of patients who had gotten a solid organ transplant.

The South San Francisco, Calif.-based company said results from the first phase 3 study for Tab-cel and the submission of an EU conditional marketing authorization application are expected in the first half of 2019.